Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1 Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4 Clinically useful cancer chemotherapeutic.
* VAT and and shipping costs not included. Errors and price changes excepted
